NCT04617002 2025-08-20Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline GliomasJazz PharmaceuticalsApproved for marketing
NCT05392374 2022-05-26Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine GliomasJazz PharmaceuticalsNo longer available3 FDA
NCT03134131 2022-03-14Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade GliomasJazz PharmaceuticalsNo longer available3 FDA